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CD95 (Fas, APO-1) is a death receptor in the plasma membrane
that specifically triggers apoptosis when appropriately stimulated
on the surface of sensitive cells (Krammer et al, 1994; Nagata,
1997). The ligand for CD95 (CD95-L) is expressed by activated
cytotoxic T lymphocytes (Suda et al, 1995) and natural killer cells
(Eischen et al, 1996; Oshimi et al, 1996). Signals through CD95
can contribute to tumour cell death induced by these immunologic
killer cells in vitro (Mori et al, 1997; Williams et al, 1997). Recent
reports have shown that treatment with cytotoxic drugs can up-
regulate tumour cell expression of CD95, and that these cells
coincidentally become more responsive to CD95 signalling (Fulda
et al, 1997; Müller et al, 1997; Williams et al, 1997).
Multiple mechanisms are employed by tumour cells to develop
resistance to CD95 signalling. Reduction or loss of CD95 on the
cell surface has been reported to desensitize leukaemia cells to
treatment with an agonistic anti-CD95 antibody (Ab) (Landowski
et al, 1997a; Martinez-Lorenzo et al, 1998). Mutation of the
cytoplasmic region of the cd95 gene has been detected in a subset
of multiple myeloma patients (Landowski et al, 1997b).
Disruption of the downstream protein caspase-8 (FLICE) in the
CD95 signalling pathway by overexpression of the cellular
FLICE-inhibitory protein (cFLIP) results in resistance to the
cytotoxic effects of both CD95 and TNF-R1; in the first report of
its kind, both melanoma cell lines and malignant melanoma
tumours were reported to overexpress cFLIP, and were resistant to
signals through CD95 (Irmler et al, 1997). However, cells that are
resistant to CD95-mediated signalling can be sensitized by treat-
ment with cycloheximide (CHX), actinomycin D, brefeldin A,
or interferon (INF)-g (von Reyher et al, 1998), although the mech-
anism for sensitization remains unclear.
Mammalian cells respond to ionizing irradiation in a variety of
ways, depending on the type and condition of the cell. In response
to DNA damage, the tumour suppressor protein p53 activates two
opposing cellular pathways, one resulting in cell-cycle arrest and
one triggering apoptosis (reviewed in Ashkenas and Werb, 1996).
Thymocytes are highly sensitive to g-irradiation and die rapidly by
apoptosis in a p53-dependent fashion following a single dose of
1 Gy (Clarke et al, 1993; Lowe et al, 1993). Carcinoma cells are
more resistant to the effects of ionizing irradiation; in one recent
study, a single large dose of g-rays (> 12 Gy) induced measurable
cell death in some, but not all carcinoma cell lines (Zhan et al,
1994). Human carcinoma patients typically cannot be irradiated
with high doses; instead, clinical irradiation is routinely fraction-
ated into relatively small, daily doses (Lichter and Lawrence,
1995).
We have previously reported that treatment of tumour cells with
ionizing radiation induces up-regulation of surface CD95 expres-
sion, but only in cells exhibiting wild-type p53 activity (Sheard
et al, 1997). To evaluate whether ionizing irradiation might
contribute to tumour cell vulnerability by increasing the response
to CD95-mediated apoptotic signals, human epithelial tumour
cells were treated with high-dose or fractionated low-dose
g-irradiation and examined for susceptibility to CD95-mediated
apoptosis.
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Summary Signals through the CD95 surface receptor can specifically induce apoptosis. Some tumour cell lines are sensitive to CD95
signals, and insensitive cells can be converted to a sensitive phenotype if given appropriate treatment. To determine whether the apoptotic
response of tumour cells to signalling through CD95 might be enhanced by ionizing irradiation, carcinoma cells were treated with either
single-dose or fractionated g-irradiation. The response to treatment with an agonist anti-CD95 antibody was enhanced by pretreatment with
either a single large dose or daily fractionated radiation. Fractionated irradiation induced cumulative and prolonged up-regulation of CD95
expression in cell lines bearing functional p53. Since two of four cell lines exhibiting heightened responsiveness to CD95-mediated signals
following fractionated irradiation express mutant p53 and displayed little or no up-regulation of CD95, enhanced responsiveness did not
correlate with p53 status and CD95 up-regulation. Continuous inhibition of CD95/CD95–ligand interactions during fractionated irradiation
provided no protective effect to cells, arguing that autologous CD95/CD95–ligand interactions did not contribute to the direct lethal effect of
irradiation. We conclude that fractionated g-irradiation provides an extended period of time when carcinoma cells are more responsive to
CD95-mediated signals in vitro.
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Cell cultures
Human colorectal carcinoma (HCT116 and HT29), breast
adenocarcinoma (MCF-7, BT549, MDA-MB231), breast ductal
carcinoma (T47D), cervical carcinoma (HeLa) and osteosarcoma
(SAOS-2) cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM). For experiments involving a single dose of
radiation, cells were plated at sub-confluence in 75 cm2 tissue
culture flasks (Nalge Nunc International, Denmark) 1 day prior to
irradiation, and maintained in 10% fetal calf serum (FCS). During
dose-fractionated experiments, cell cultures consistently expanded
to confluency, regardless of low starting concentrations; fresh
medium containing 1% FCS (except where noted) was supplied
every 3 days, 8 h after irradiation (to avoid conflict between
transient post-irradiation p53 activity and serum-derived mito-
genic signals), and 1 day before anti-CD95 treatment (to avoid
conflict between CD95-induced apoptotic signals and mitogenic
signals from freshly-administered serum). The status of p53 has
been reported for all cell lines studied.
Radiation treatment
Cell lines were g-irradiated from a 60Co source (dose rate 1.30 Gy
min–1). To assess basal levels of CD95, equivalent cell cultures
were mock-treated by removing from incubators and tightening
caps during the irradiation periods. For fractionated irradiation,
cells were exposed daily to 2 Gy for 8 consecutive weekdays,
Tuesday to Friday in the first week, Monday to Thursday in the
second week.
Induction and inhibition of CD95-mediated apoptosis
Eight hours after completion of irradiation, agonist anti-CD95
IgM monoclonal Ab (clone CH11, Immunotech, Westbrook, ME,
USA) was added directly to cell cultures for a final concentration
of 1 mg ml–1 (in CD95-resistant cells) or 0.2 mg ml–1 (in partially-
sensitive cells), and cells were incubated for 44 h (in single-dose
experiments) or 20 h (in fractionated-dose experiments) in 5%
carbon dioxide at 37°C prior to harvesting. Prior to addition of
agonist Ab, CD95-resistant cells were pretreated with cyclohex-
imide (10 mg ml–1) (SIGMA, St Louis, MO, USA) for 30 min.
To inhibit CD95-mediated apoptosis, the previously described
antagonistic F(ab¢)2 Ab fragments (anti-APO-1) (Dhein et al,
1995) were added at 1 mg ml–1 30 min before addition of agonist
Ab in single-dose experiments, or immediately after every
exchange of medium when examining potential CD95/CD95-L
interactions during fractionated irradiation.
DNA content analysis
For measurement of DNA content, adherent and floating cells
were washed separately, pooled together, and incubated for at least
4 h at 4°C in 400 ml DNA staining solution (50 mg ml–1 propidium
iodide, 0.1% Triton X-100, 0.07% RNase, 0.1% sodium
chloride). Cells were analysed by flow cytometry in their staining
solution diluted to 0.8 ml with modified Hank’s balanced salt solu-
tion (HBSS). A 630 nm band-pass filter was used to collect red
fluorescence. In each histogram, a gate was applied to the lowest
spectrum of the linear FL3 channel at the distinct border between
apoptotic cells and subcellular debris. Data were acquired in linear
mode instead of logarithmic mode to reduce the negative aspect
associated with setting subjective gates on forward and side-
scatter parameters when delineating between late apoptotic events
and subcellular debris (late apoptotic cells are a source of debris-
related noise), which was more problematic when very low-
staining FL3 signals were included into analyses using a
logarithmic scale.
TdT-mediated dUTP nick end labelling (TUNEL)
TUNEL technique was performed using a kit (Boehringer
Mannheim, Mannheim, Germany) according to instructions
provided by the manufacturer, with several modifications. Briefly,
harvested cells (adherent plus floating) were transferred to ‘eppen-
dorf’ tubes and washed twice in modified HBSS containing 0.2%
bovine serum albumin (BSA) and 0.1% sodium azide (NaN3); to
avoid excessive cell loss during the many washing steps, all
washes were performed by centrifuging cells for 8 min at 300 g
(in early washes), aspirating supernatants to a minimal volume
using individual disposable pipettes, and adding a few drops of
medium to each tube for adequate volume during subsequent
vortexing. Cells were fixed in 4% paraformaldehyde for 30 min at
room temperature. After two washes in phosphate-buffered saline
(PBS), cells were resuspended in permeabilization solution (0.1%
Triton X-100, 0.1% sodium citrate) for 5 min and washed twice
(spin rate was henceforth increased to 400 G to improve cell
yield). To relieve compaction of DNA by histones, cells were incu-
bated in proteinase K (20 mg ml–1) at 37°C for 20 min. Following
two washes, cells were incubated in the provided staining solution
for 2 h at 37°C, washed twice, and analysed by flow cytometry.
Determination of surface protein expression
Cells were harvested with 0.1% trypsin, 0.25% EGTA in modified
HBSS without calcium or magnesium, and maintained in modified
HBSS containing 0.2% BSA and 0.1% NaN3. Cells were washed
twice, stained with fluorescein isothiocyanate (FITC)-conjugated
monoclonal anti-human CD95 (clone UB2) or FITC-IgG1 isotype
control Ab (Immunotech, Westbrook, ME, USA), washed twice,
and analysed by flow cytometry using an EPICS XL (Coulter,
Hialeah, FL, USA). The voltage applied to the FL1 channel was
selected for each treatment-group in a given cell type so that the
mean fluorescence intensity (MFI) of irrelevant Ab-treated
controls was similar. Indices of MFI values were calculated using
the formula: MFI Index = (MFI of anti-CD95 Ab-stained
cells/MFI of irrelevant Ab-stained cells). Dead cells and debris
were excluded according to their increased staining with
propidium iodide and low forward scatter properties. At least
10 000 viable cells were interrogated for each sample.
RESULTS
Response to signals through CD95 after a single large
dose of g-radiation
To evaluate whether ionizing radiation can sensitize tumour cells
to apoptotic signalling through CD95, HCT116 colorectal
carcinoma cells were treated with 16-Gy g-rays. Eight hours later,
irradiated and control cells were treated with CHX, with an
agonistic cross-linking anti-CD95 Ab, or both, and then incubated
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staining with propidium iodide and analysing by flow cytometry.
Only a low percentage of untreated HCT116 cells contained a
DNA content less than observed in G1 phase of the cell-cycle
(sub-G1); (we avoid the common term ‘subdiploid’, since many
tumour cell lines in G1 phase contain an aneuploid number of
chromosomes). Treatment of unirradiated control cells with
agonist anti-CD95 Ab alone had no significant effect on the
percentage of sub-G1 events (Figure 1A, upper left panels), indi-
cating that HCT116 cells are resistant to signals through CD95.
Treatment with CHX alone had no reproducible effect on cell
viability, but the combination of CHX with anti-CD95 Ab induced
a significant increase in the percentage of sub-G1 events (Figure
1A, left panels). This increase in cell-death was almost completely
abolished by prior incubation with an antagonist (non-signalling)
anti-CD95 Ab.
A small increase in the percentage of sub-G1 events was
observed 2 days after g-irradiation with 16 Gy (Figure 1A, upper
panels). As in unirradiated controls, the viability of irradiated cells
was not affected by agonist anti-CD95 Ab alone, indicating that
large-dose irradiation by itself does not sensitize these resistant
cells to CD95 signals. A substantial increase in sub-G1 events was
observed when radiation treatment was combined with CHX plus
agonist anti-CD95 Ab, and this increase was larger than observed
after treatment with CHX plus agonist anti-CD95 Ab in the
absence of irradiation (Figure 1A).
Enhanced responsiveness was also observed when cells were
examined for DNA strand breaks by TUNEL staining. Significant
DNA breakage was observed in irradiated cells treated with CHX
plus agonistic anti-CD95 Ab (Figure 1B), which was confirmed in
a parallel DNA content analysis. TUNEL staining provided poorer
resolution of microscopically confirmed CD95-induced carcinoma
cell death than did DNA content analysis in these experiments.
These results suggest that a large dose of g-radiation can enhance
the response of CD95-sensitized tumour cells to signals through
CD95.
Cumulative up-regulation of CD95 when g-irradiation is
fractionated into daily doses
One mechanism for enhancing the apoptotic response to CD95-
mediated signalling may be through up-regulation of CD95
surface expression. CD95 expression is known to be regulated, in
part, by the p53 protein (Owen-Schaub et al, 1995), and carcinoma
cells exhibiting wild-type p53 activity were shown to up-regulate
CD95 expression 8 h after a high dose of g-rays (Sheard et al,
1997). However, clinical irradiation is usually fractionated into
low doses, and it remained unknown whether surface expression
of CD95 is sufficiently stable to accumulate during an extended
g-Rays enhance response to CD95 signals 1691
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Figure 1 Effect of signals through CD95 on viability of tumour cells g-irradiated with a single large dose. Eight hours after g-irradiation, HCT116 cells were
pretreated with CHX alone (10 mg ml–1) for 30 min, treated with agonist anti-CD95 Ab alone (1 mg ml–1), or treated with both CHX and then agonist Ab. To
evaluate the specificity of killing, controls were incubated with an antagonist anti-CD95 Ab 30 min before addition of agonist Ab. After 44 h, cells were harvested
and stained for analyses by flow cytometry, as described in Materials and Methods. (A) DNA content was analysed for individual cells by staining DNA with
propidium iodide. Peaks representing cells in G1 phase of the cell-cycle are located at channel 400. The percentage of events detected with a DNA-content
less than in G1 phase of the cell-cycle is given in each panel. Similar results were obtained in four independent experiments. (B) DNA strand breaks were
detected by TUNEL staining. The percentage of specific staining with dUTP-FITC is given in each panel and was calculated as follows: (% positive in TUNEL
reaction) 2 (% positive in controls stained with TdT only)
Table 1 Surface CD95 expression in single-dose- or sequentially-irradiated
cells expressing wild-type p53
MFI Indexa
Cell lines Untreated 16 Gy Mock-irradiated (8´) 2 Gy (8´)
HCT116 3.24 5.85 2.85b 7.01b
MCF-7 1.80 5.42 1.63 5.19
ZR-75.1 9.85 17.0 10.8 19.6
aValues for MFI Index were calculated as described in Materials and
Methods. bMaintained in 1% FCS; other cells were maintained in 10% FCS.course of daily fractionated treatment. To address this question,
multiple cell lines with wild-type statuses of p53 were g-irradiated
with 2 Gy on 8 consecutive weekdays and examined 1 day later for
CD95 expression levels. HCT116 and MCF-7 cells constitutively
express a low level of CD95 on their cell surface, and this level is
unaffected by repetitive mock-irradiation (Figure 2A, top panels).
As a control, these cells were treated with a single dose of 2 Gy,
resulting in moderate up-regulation of CD95, or with 16 Gy,
resulting in significantly higher CD95 expression (middle panels).
Fractionation of the 16 Gy dose into 8 daily doses of 2 Gy (lower
panels) resulted in an approximately equal enhancement of CD95
expression as obtained with the single large dose (Table 1). Similar
results were obtained with ZR-75.1 cells (Table 1).
Six cell lines reported to exhibit aberrant p53-activity were also
examined, to determine whether fractionated irradiation might affect
CD95 expression in the large subset of cancer cells that possess
abnormal p53 activity. A single dose of 16 Gy induced slight up-
regulation in HT29 cells, but not in the other five cell lines examined
(Figure 2B). Dose-fractionated irradiation reproducibly induced
slight up-regulation in two lines (HT29 and MDA-MB231), but had
no significant effect on CD95 expression in the remaining four lines.
All cell lines were able to up-regulate CD95 after treatment with
interferon-g, regardless of p53 status (data not shown). Taken
together, these results indicate that up-regulation of CD95 is cumu-
lative during fractionated g-irradiation, but abundant up-regulation
is limited to those cells bearing normal wild-type p53.
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Figure 2 Regulation of surface CD95 expression after g-irradiation. Cells were treated (thick lines) with single-dose or fractionated irradiation. Controls (thin
lines) were untreated or mock-irradiated. Cells were stained with anti-CD95 (solid lines) or irrelevant Ab (dotted lines) 1 day after completion of irradiation, and
analysed by flow cytometry. (A) HCT116 and MCF-7 cells, reported to express functional wild-type p53 activity. (B) Cell lines reported to express aberrant p53
activity. A minimum of three independent experiments was performed for each cell lineResponse to signals through CD95 after fractionated
g-irradiation
To examine whether fractionated radiation treatment enhances the
response of CD95-resistant carcinoma cells to CD95-mediated
signals, HCT116 and MCF-7 cells were g-irradiated with 2 Gy on
8 consecutive weekdays. Eight hours after completion of fraction-
ated irradiation, cells were treated with CHX and/or agonist anti-
CD95 Ab, incubated another 20 h, and examined for DNA content.
Incubation with agonist anti-CD95 Ab alone did not alter the
percentage of sub-G1 events in either mock-irradiated or sequen-
tially-irradiated cells, indicating that fractionated irradiation did
not overcome the inherent resistance of these tumour cells to
CD95-mediated signals (Figure 3A). Incubation with agonist anti-
CD95 Ab in the presence of CHX resulted in a substantially larger
increase in the percentage of sub-G1 events in sequentially-irradi-
ated cells than in identically treated mock-irradiated cells (Figure
3A). Prior incubation with antagonist anti-CD95 Ab specifically
g-Rays enhance response to CD95 signals 1693
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Figure 3 Effect of CD95-mediated signalling on viability of carcinoma cells treated with fractionated g-irradiation. Cells were irradiated with 2 Gy g-rays daily on
8 consecutive weekdays. (A) CD95-resistant cell lines HCT116 and MCF-7. Eight hours after the final irradiation, cells were pretreated with CHX (10 mg ml–1),
treated with agonist anti-CD95 Ab (1 mg ml–1), or both. Cells were harvested 20 h later, 42 h after the final exchange of medium, and analysed as in Figure 1A.
(B) Partially-sensitive cell lines HT29 and T47D, treated with agonist anti-CD95 Ab (0.2 mg ml–1) in the absence of CHX. Specific groups were subject to
continuous incubation with antagonist anti-CD95 Ab throughout the course of fractionated irradiation, as shown. T47D cells contained substantial populations
with approximately tetraploid and octaploid numbers of chromosomes. The lowest G1 peak of T47D cells was positioned at channel 200 to permit viewing of
near-octaploid cells. Results are representative of three independent experiments for each cell line1694 MA Sheard et al
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Binhibited induction of sub-G1 events. Thus, HCT116 and MCF-7
cells were rendered more responsive to CD95-mediated signals
by fractionated irradiation, but only when supplied sensitizing
pretreatment (e.g. CHX).
To extend these observations, two partially-sensitive carcinoma
cell lines that do not require sensitizing pretreatment were exam-
ined. HT29 and T47D cells undergo a modest degree of apoptosis
in response to treatment with agonist anti-CD95 Ab alone, but
only after relatively long incubation times. Incubation with agonist
Ab induced a small increase in sub-G1 events in mock-irradiated
cells, but a significantly larger increase was reproducibly observed
after identical treatment of sequentially-irradiated cells (Figure
3B). These data indicate that fractionated g-irradiation alone is
sufficient to enhance the vulnerability of partially-sensitive carci-
noma cells to CD95-mediated apoptosis. Since HT29 and T47D
cells express mutant p53 and exhibit little or no up-regulation of
CD95 after fractionated irradiation (Figure 2B), the observed
enhancement of responsiveness to CD95-mediated signals was
independent of wild-type p53 status and CD95 up-regulation.
The T47D cells in our experiments contained subpopulations
with approximately tetraploid (4N) and octaploid (8N) numbers of
chromosomes (Figure 3B, channels 400 and 800), as previously
reported (Graham et al, 1989). Following fractionated irradiation,
an apparent accumulation of T47D and HCT116 cells in peaks
containing 4N was observed (Figure 3 A, B). This accumulation
was due, at least in part, to irradiation-induced generation of poly-
ploidy, since these cells accumulated near-octaploid and eventu-
ally near-16N populations after fractionated irradiation (data not
shown), and should not be interpreted as indicative of G2 cell-
cycle arrest at these low doses.
To investigate whether autologous CD95/CD95-L signalling
(Friesen et al, 1996; Fulda et al, 1997; Müller et al, 1997) might be
involved in radiation-induced death in the model studied here,
sequentially-irradiated cells were continuously incubated in the
presence of antagonist anti-CD95 Ab throughout the 11 day
protocol from the first dose of 2 Gy to harvest. Continuous
culturing with antagonist anti-CD95 Ab did not prevent the forma-
tion of either radiation-induced sub-G1 events (Figure 3 A, B) or
classical radiation-induced morphology involving cellular enlarge-
ment and vacuolation (Figure 4 A, B), even though the same
concentration of antagonist Ab inhibited the formation of both
sub-G1 events and morphological changes induced by agonist
anti-CD95 Ab treatment. Relatedly, continuous inhibition of
CD95/CD95-L interactions did not prevent radiation-induced
polyploidy in T47D (Figure 3B) and HCT116 (data not shown)
cells. Taken together, these results indicate that autologous
CD95/CD95-L signalling did not mediate the damaging effects of
fractionated g-irradiation on the four cell lines examined.
DISCUSSION
Many proteins are only transiently expressed in cells. For example,
p53 expression increases 2–3 h after treatment of MCF-7 cells with
ionizing radiation, but then rapidly declines (Lu and Lane, 1993).
Transiently expressed proteins responding to cellular stress would
not be expected to accumulate over time during daily dose-fraction-
ation. However, evaluation of CD95 expression during fractionated
g-irradiation of p53wild-type cells reveals that fractionation of treatment
into small daily doses results in strong up-regulation of CD95
expression levels, demonstrating that CD95 is sufficiently stable on
the cell surface to allow accumulation during dose-fractionation.
This supports the possibility that clinical radiotherapy of wild-type
p53-expressing tumours may result in cumulative and prolonged
elevation of CD95 expression, which may endure throughout the
entire course (e.g. 30 fractions) of radiation therapy.
Daily fractionated g-irradiation enhanced the response to CD95-
mediated signals in four of four carcinoma cell lines. However,
irradiation-induced increases in CD95 expression alone were not
sufficient to sensitize CD95-resistant cells to CD95-mediated
signals in the absence of CHX, and the responsiveness to CD95-
mediated signals in two of the four cell lines was increased in spite
of little or no detectable up-regulation of CD95, indicating that
CD95 up-regulation is not a critical factor for enhancing the
responsiveness to CD95-mediated signals. This latter finding is
similar to a report that inhibition of protein export with brefeldin A
prevents up-regulation of surface CD95 and yet sensitizes carci-
noma cells to CD95-mediated signals (von Reyher et al, 1998).
The question of whether, and to what extent, increases in CD95
expression can influence the apoptotic response to CD95-mediated
signals has not been specifically addressed in this work. Notably, it
has been reported that sensitization to CD95-mediated signalling
can be obtained in CD95-resistant MCF-7 cells by genetically
engineered overexpression of CD95 in the presence of protein A or
sphingomyelinase (Jäättelä et al, 1995), leaving open the possi-
bility that the magnitude of increased CD95 expression may influ-
ence the sensitivity of CD95-resistant cells.
The possibility that induction of tumour cell death by radiation
treatment might involve autologous killing through CD95/CD95-L
interactions has been suggested by the following observations: (i)
ionizing radiation stimulates production of ceramide (Haimovitz-
Friedman et al, 1994), (ii) g-radiation-induced production of
ceramide can induce up-regulation of CD95-L (Herr et al, 1997),
(iii) disruption of the CD95/CD95-L signalling pathway in
leukaemia cells inhibited ceramide-induced apoptosis (Herr et al,
1997). Furthermore, it was reported that autologous CD95/CD95-
L signalling can be observed following cytotoxic treatments of
some leukaemia, hepatoma and neuroblastoma cells (Friesen et al,
1996; Müller et al, 1997; and Fulda et al, 1997 respectively).
However, inhibition of CD95/CD95-L interactions provided no
protection from the lethal effect of daily fractionated g-irradiation
in the carcinoma cells studied here. Similarly, it has been previ-
ously reported that g-irradiation (12 Gy) of a CD95-resistant
subclone of Jurkat lymphoid cells induced cell death as efficiently
as in CD95-sensitive parental cells (Eischen et al, 1997). The
absence of autologous CD95/CD95-L signalling in the direct lethal
effect of fractionated g-irradiation on CD95-partially-sensitive
cells suggests that the radiation-enhanced response to signals
through CD95 might be fully exploitable using other modalites for
ligating CD95. An additional sensitizing agent would be required
to realize a similar benefit in CD95-resistant cells.
In summary, the present study indicates that CD95-partially-
sensitive carcinoma cells, and also CD95-resistant cells which are
pretreated with a sensitizing agent (e.g. CHX), become more
responsive to CD95-mediated apoptotic signals after fractionated
g-irradiation. No evidence was found to suggest that autologous
CD95/CD95-L signalling was active in the fractionated radiation-
induced death of the four carcinoma cell lines tested. Since the
CD95-independent nature of fractionated radiation-induced death
was coupled with increased responsiveness to CD95-mediated
signals, utilization of the heightened responsiveness of these irra-
diated carcinoma cells to CD95-mediated signalling probably
requires an exogenous source of CD95 ligation.
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